Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Wraps Up NovaScreen Acquisition

NEW YORK, Oct. 4 (GenomeWeb News) - Caliper Life Sciences has completed its acquisition of NovaScreen Biosciences for up to $30 million, the companies said today.

 

Caliper can now set its sights on the outsourced assay-development and -screening markets, "especially" the secondary screening and profiling -services market, the company said in a statement. The acquisition could also enable Caliper to play a greater role in the kinase-screening market.

 

As GenomeWeb News reported last month, Caliper Life Sciences planned to acquire NovaScreen for $22 million, subject to certain financial parameters, and up to an additional $8 million, depending on revenue milestones over the next 30 months. Eighty percent of the payments will be made in Caliper common stock and 20 percent in cash.

 

Caliper said it expects NovaScreen to contribute approximately $2 million to its revenues.

 

Hanover, Md.-based NovaScreen focuses on in vitro screening assays and in silico predictive screening tools, with particular expertise in receptor pharmacology.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.